Press Release
June 12, 2003


BRENTWOOD, TN AND BIRMINGHAM, AL - June 12, 2003 - VDDI Pharmaceuticals, a biopharmaceutical development company, and the University of Alabama at Birmingham today announced receipt of allowance for a patent from the United States Patent and Trademark Office for a NADs inhibitor (nicotinamide adenine dinculeotide synthetase) to treat hospital acquired fungal infections.

This is the second patent of its kind produced by the partnership between VDDI and UAB. The two organizations have more than 20 patents pending in this family of antibiotics in the U.S. and internationally, covering the NADs inhibitor technology for all human, animal, and plant uses.

With this technology, the compounds interact with a unique, and unexploited, microbial target (NAD synthetase), to inhibit bacterial and fungal growth. It was discovered at UAB's Center for Biophysical Sciences and Engineering and licensed exclusively to VDDI by the UAB Research Foundation.

"Hospital acquired fungal infections, particularly those resistant to currently available therapies, are a critical health care concern and a difficult medical condition to treat," said Dr. R. Stephen Porter, President and CEO of VDDI. "That is the target of this new chemical class, and we are anxious to develop it further."

The compounds, which are also effective against bacterial targets, including anthrax, are being further developed under a cooperative agreement between VDDI and the Department of Defense.

VDDI Pharmaceuticals is a privately held biopharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. VDDI's initial focus is on developing products for infectious diseases of bacterial or fungal origins, a global market currently exceeding $30 billion per year.

The UABRF is the technology transfer organization of the University of Alabama at Birmingham. The UAB-CBSE is dedicated to understanding the structure and function of macromolecules as applied to new drug discovery via intelligent or structure-based, chemical design.

Statements included in this press release that are not historical in nature are "forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including but not limited to, our failure to successfully commercialize our products, costs and delays in the development and FDA approval of our products; our inability to enter into or maintain, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of our products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others general economic conditions; the failure of our products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

VDDI Pharmaceuticals is on the Internet at The UAB-CBSE can be located at

CONTACT: R. Stephen Porter, Pharm.D.
President and CEO
VDDI Pharmaceuticals
1616 Westgate Circle
Brentwood, TN 37027-0018

Larry DeLucas, O.D., Ph.D., D.Sc. (Hon.)
1025 18th Street South
Birmingham, AL 35205-4832

Lucy C. Hicks
1120G Administration Building
701 20th Street South
Birmingham, Alabama 35294-0111

go back go next


Site created and maintained by Opposable Thumb Digital.